These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31053413)

  • 21. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
    Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
    Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma.
    Liu H; Yuan SJ; Chen YT; Xie YB; Cui L; Yang WZ; Yang DX; Tian YT
    World J Gastroenterol; 2013 Aug; 19(31):5138-43. PubMed ID: 23964149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
    Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
    Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.
    Kim KJ; Moon D; Kong SJ; Lee YS; Yoo Y; Kim S; Kim C; Chon HJ; Kim JH; Choi KJ
    Gene Ther; 2021 Apr; 28(3-4):186-198. PubMed ID: 33149278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
    Ramelyte E; Tastanova A; Balázs Z; Ignatova D; Turko P; Menzel U; Guenova E; Beisel C; Krauthammer M; Levesque MP; Dummer R
    Cancer Cell; 2021 Mar; 39(3):394-406.e4. PubMed ID: 33482123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
    Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
    Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
    Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
    J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.